Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers

A. Bravermanová, M. Viktorinová, F. Tylš, T. Novák, R. Androvičová, J. Korčák, J. Horáček, M. Balíková, I. Griškova-Bulanova, D. Danielová, P. Vlček, P. Mohr, M. Brunovský, V. Koudelka, T. Páleníček,

. 2018 ; 235 (2) : 491-503. [pub] 20180105

Language English Country Germany

Document type Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19012946

Grant support
NV15-33250A MZ0 CEP Register

RATIONALE: Disruption of auditory event-related evoked potentials (ERPs) P300 and mismatch negativity (MMN), electrophysiological markers of attentive and pre-attentive cognitive processing, is repeatedly described in psychosis and schizophrenia. Similar findings were observed in a glutamatergic model of psychosis, but the role of serotonergic 5-HT2A receptors in information processing is less clear. OBJECTIVES: We studied ERPs in a serotonergic model of psychosis, induced by psilocybin, a psychedelic with 5-HT2A/C agonistic properties, in healthy volunteers. METHODS: Twenty subjects (10M/10F) were given 0.26 mg/kg of psilocybin orally in a placebo-controlled, double-blind, cross-over design. ERPs (P300, MMN) were registered during the peak of intoxication. Correlations between measured electrophysiological variables and psilocin serum levels and neuropsychological effects were also analyzed. RESULTS: Psilocybin induced robust psychedelic effects and psychotic-like symptoms, decreased P300 amplitude (p = 0.009) but did not affect the MMN. Psilocybin's disruptive effect on P300 correlated with the intensity of the psychedelic state, which was dependent on the psilocin serum levels. We also observed a decrease in N100 amplitude (p = 0.039) in the P300 paradigm and a negative correlation between P300 and MMN amplitude (p = 0.014). CONCLUSIONS: Even though pre-attentive cognition (MMN) was not affected, processing at the early perceptual level (N100) and in higher-order cognition (P300) was significantly disrupted by psilocybin. Our results have implications for the role of 5-HT2A receptors in altered information processing in psychosis and schizophrenia.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012946
003      
CZ-PrNML
005      
20201112183420.0
007      
ta
008      
190405s2018 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00213-017-4807-2 $2 doi
035    __
$a (PubMed)29302713
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Bravermanová, Anna $u National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic. First Faculty of Medicine, Charles University Prague, Kateřinská 32, 121 08, Prague 2, Czech Republic.
245    10
$a Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers / $c A. Bravermanová, M. Viktorinová, F. Tylš, T. Novák, R. Androvičová, J. Korčák, J. Horáček, M. Balíková, I. Griškova-Bulanova, D. Danielová, P. Vlček, P. Mohr, M. Brunovský, V. Koudelka, T. Páleníček,
520    9_
$a RATIONALE: Disruption of auditory event-related evoked potentials (ERPs) P300 and mismatch negativity (MMN), electrophysiological markers of attentive and pre-attentive cognitive processing, is repeatedly described in psychosis and schizophrenia. Similar findings were observed in a glutamatergic model of psychosis, but the role of serotonergic 5-HT2A receptors in information processing is less clear. OBJECTIVES: We studied ERPs in a serotonergic model of psychosis, induced by psilocybin, a psychedelic with 5-HT2A/C agonistic properties, in healthy volunteers. METHODS: Twenty subjects (10M/10F) were given 0.26 mg/kg of psilocybin orally in a placebo-controlled, double-blind, cross-over design. ERPs (P300, MMN) were registered during the peak of intoxication. Correlations between measured electrophysiological variables and psilocin serum levels and neuropsychological effects were also analyzed. RESULTS: Psilocybin induced robust psychedelic effects and psychotic-like symptoms, decreased P300 amplitude (p = 0.009) but did not affect the MMN. Psilocybin's disruptive effect on P300 correlated with the intensity of the psychedelic state, which was dependent on the psilocin serum levels. We also observed a decrease in N100 amplitude (p = 0.039) in the P300 paradigm and a negative correlation between P300 and MMN amplitude (p = 0.014). CONCLUSIONS: Even though pre-attentive cognition (MMN) was not affected, processing at the early perceptual level (N100) and in higher-order cognition (P300) was significantly disrupted by psilocybin. Our results have implications for the role of 5-HT2A receptors in altered information processing in psychosis and schizophrenia.
650    _2
$a akustická stimulace $x metody $7 D000161
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a pozornost $x účinky léků $x fyziologie $7 D001288
650    _2
$a kognice $x účinky léků $x fyziologie $7 D003071
650    _2
$a klinické křížové studie $7 D018592
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a elektroencefalografie $x účinky léků $x metody $7 D004569
650    _2
$a kognitivní evokované potenciály P300 $x účinky léků $x fyziologie $7 D018913
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a halucinogeny $x farmakologie $7 D006213
650    _2
$a zdraví dobrovolníci pro lékařské studie $7 D064368
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a psilocybin $x škodlivé účinky $x farmakologie $7 D011562
655    _2
$a klinické zkoušky kontrolované $7 D018848
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Viktorinová, Michaela $u National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic. Third Faculty of Medicine, Charles University Prague, Ruská 87, 100 00, Praha 10, Czech Republic.
700    1_
$a Tylš, Filip $u National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic. Third Faculty of Medicine, Charles University Prague, Ruská 87, 100 00, Praha 10, Czech Republic.
700    1_
$a Novák, Tomáš $u National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic. Third Faculty of Medicine, Charles University Prague, Ruská 87, 100 00, Praha 10, Czech Republic.
700    1_
$a Androvičová, Renáta $u National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic. Third Faculty of Medicine, Charles University Prague, Ruská 87, 100 00, Praha 10, Czech Republic.
700    1_
$a Korčák, Jakub $u National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic. Third Faculty of Medicine, Charles University Prague, Ruská 87, 100 00, Praha 10, Czech Republic.
700    1_
$a Horáček, Jiří $u National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic. Third Faculty of Medicine, Charles University Prague, Ruská 87, 100 00, Praha 10, Czech Republic.
700    1_
$a Balíková, Marie $u First Faculty of Medicine, Charles University Prague, Kateřinská 32, 121 08, Prague 2, Czech Republic.
700    1_
$a Griškova-Bulanova, Inga $u Institute of Biosciences, Vilnius University, Sauletekio ave 7, 102 57, Vilnius, Lithuania.
700    1_
$a Danielová, Dominika $u National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic. Third Faculty of Medicine, Charles University Prague, Ruská 87, 100 00, Praha 10, Czech Republic.
700    1_
$a Vlček, Přemysl $u National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic. Third Faculty of Medicine, Charles University Prague, Ruská 87, 100 00, Praha 10, Czech Republic.
700    1_
$a Mohr, Pavel $u National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic. Third Faculty of Medicine, Charles University Prague, Ruská 87, 100 00, Praha 10, Czech Republic.
700    1_
$a Brunovský, Martin $u National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic. Third Faculty of Medicine, Charles University Prague, Ruská 87, 100 00, Praha 10, Czech Republic.
700    1_
$a Koudelka, Vlastimil $u National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic.
700    1_
$a Páleníček, Tomáš $u National Institute of Mental Health, Topolová 748, 250 67, Klecany, Czech Republic. tomas.palenicek@nudz.cz. Third Faculty of Medicine, Charles University Prague, Ruská 87, 100 00, Praha 10, Czech Republic. tomas.palenicek@nudz.cz.
773    0_
$w MED00003990 $t Psychopharmacology $x 1432-2072 $g Roč. 235, č. 2 (2018), s. 491-503
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29302713 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20201112183417 $b ABA008
999    __
$a ok $b bmc $g 1392256 $s 1051251
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 235 $c 2 $d 491-503 $e 20180105 $i 1432-2072 $m Psychopharmacology $n Psychopharmacology $x MED00003990
GRA    __
$a NV15-33250A $p MZ0
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Archiving options